Daniel B. Costa

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge et al. · New England Journal of Medicine · 2010 · 4.5K citations

Medicine, Oncology, Pharmacology +14

Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer

Alice T. Shaw, Sai‐Hong Ignatius Ou, Yung‐Jue Bang et al. · New England Journal of Medicine · 2014 · 2K citations

Medicine, Oncology, Pharmacology +17

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor <i>EML4-ALK</i>

Alice T. Shaw, Beow Y. Yeap, Mari Mino–Kenudson et al. · Journal of Clinical Oncology · 2009 · 1.9K citations · Full text

Medicine, Genetics, Oncology +17

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Shohei Koyama, Esra A. Akbay, Yvonne Y. Li et al. · Nature Communications · 2016 · 1.6K citations · Full text

Medicine, Immunology, Oncology +17

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

D. Ross Camidge, Yung‐Jue Bang, Eunice L. Kwak et al. · The Lancet Oncology · 2012 · 1.3K citations

Medicine, Oncology, Pharmacology +15